Csl (QX)【CSLLY】銘柄情報

Csl Ltd (QX) (CSLLY) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

16.35

( - )

買値

16.35

売値

16.35

出来高

0.00 日の範囲 0.00

16.29 52 週間の範囲 89.71

時価総額

7.883B

前日終値

16.35

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 1,609,298

発行済株式数

482,130,812

配当利回り

2.92

PER

24.29

1 株当たり利益 (EPS)

2.86

歳入

15.41B

純利益

1.4B

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, ... CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.csl.com

本社

Melbourne, Australia

設立

2026

Csl Ltd (QX) is listed in the Healthcare sector of the その他OTC with ticker CSLLY. The last closing price for Csl (QX) was US$16.35. Over the last year, Csl (QX) shares have traded in a share price range of US$ 16.29 to US$ 89.71.

Csl (QX) currently has 482,130,812 shares in issue. The market capitalisation of Csl (QX) is US$7.88 billion. Csl (QX) has a price to earnings ratio (PE ratio) of 24.29.

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-1.319	-7.46505178561	17.669	17.669	16.29	876506	17.14089356	DR
4	-5.66	-25.7155838255	22.01	22.28	16.29	600799	17.75014734	DR
12	-8.56	-34.3637093537	24.91	26.61	16.29	537406	21.8397678	DR
26	-42.61	-72.2693351425	58.96	67.0632	16.29	354880	29.66330582	DR
52	-63.4	-79.4984326019	79.75	89.71	16.29	237840	39.76368593	DR
156	-86.675	-84.1300655181	103.025	109	16.29	128685	57.67798277	DR
260	-95.8817	-85.4319234227	112.2317	117.49	16.29	99156	66.78005811	DR